Allergy Immunotherapy Market size is poised to surpass USD 6 Billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024 – 2036. In the year 2022, the industry size of allergic immunotherapy was over USD 2 Billion. Because more people are developing these allergies, the market is expanding. The healthcare system is challenged by complex allergies, which cause people's health to deteriorate too much. Asthma and other allergies that affect the body's respiratory system are on the rise as a result of the environment's increasing air pollution. As per a recent report, asthma was the primary diagnosis in 38,792 hospitalizations between 2017 and 2018. Also, Asthma-related fatalities totaled 417 in 2020.
Furthermore, a rising number of immunotherapy treatments are under development to treat patients' allergies. This element is anticipated to fuel market expansion. Sublingual immunotherapy has been investigated by certain researchers for a variety of food allergies, including those to milk, peanuts, kiwis, and peaches. Numerous studies have shown that therapy cannot be effective without consistent pharmaceutical use.
Base Year |
2023 |
Forecast Year |
2024 - 2036 |
CAGR |
~10% |
Base Year Market Size (2023) |
~USD 2 billion |
Forecast Year Market Size (2036) |
~USD 6 billion |
Regional Scope |
|
Growth Drivers
Challenges
Allergy Type (Allergic Rhinitis, Asthma, Allergic Conjunctivitis)
The rhinitis segment is expected to hold a significant share of the allergy immunotherapy market during the forecast period. According to a survey, rhinitis and asthma impact 23 million people in the US each year. In the same region, an additional 50 million people suffer from another type of allergy. One of the major drivers of the market expansion is the increased investment made by major manufacturers in the development of AIT medications to treat different allergies. Therefore, it is anticipated that allergic rhinitis will fuel the segment's expansion.
Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy)
The subcutaneous immunotherapy segment would account for more than 53% of the allergy immunotherapy market. Subcutaneous immunotherapy (SCIT) is a cutting-edge method for treating allergic diseases because it alters allergic diseases by concentrating on the underlying immunological mechanism. Numerous carefully monitored clinical trials have demonstrated its efficacy and safety in the treatment of asthma, allergic rhinitis/rhino conjunctivitis, and hypersensitivity to stinging insects. Subcutaneous immunotherapy (SCIT), which is administered via injection, is frequently referred to as an "allergy shot". It provides symptomatic relief for those with asthma and allergic rhinitis and is the standard treatment for allergen desensitization. Increased prevalence of allergic disorders and high demand for improved procedures are some of the factors driving the growth of the segment. According to estimates, between 11 and 26 million people in Europe have food allergies. With a population of 7 billion people, this rate amounts to 240–550 million people who could be food allergies, which is a significant global health burden.
Our in-depth analysis of the global market includes the following segments:
Treatment |
|
Allergy Type |
|
Distribution Channels |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
APAC Market Forecast
In the Asia Pacific allergy immunotherapy market is to generate the highest revenue by the end of 2036. Also, Asia Pacific is expected to hold a share of 36% during the forecast period. In countries, such as India and China, this is mainly due to the existence of a large proportion of the younger population that are more susceptible to sensitization. Moreover, a number of factors contributing to growth in this market in the Asia Pacific region are the presence of major key players in the market, investment from them, and uptake of medicines like Sublingual Immunotherapy with an overview of long-term results as well as dosage standardization.
North American Market Statistics
North America allergy immunotherapy market is expected to hold a significant share of 27% during the forecast period. The market expansion can be attributed to the region's high frequency of allergy diseases as well as the population's increased health consciousness. According to the World Allergy Organization, allergic rhinitis is the seventh most common chronic respiratory condition in the US, affecting 10–30% of the general adult population and approximately 405 children. A few other elements boosting the expansion in the area include high-end research and development, investments made by market participants, partnerships and acquisitions with significant industry participants, and strong emphasis on manufacturing facilities.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Growing research and development activities and growing prevalence of allergies are some of the factors driving the market growth.
Ans: The market size of allergic immunotherapy is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024 – 2036.
Ans: The major players in the market are ALK, Stallergenes Greer, Mylan N.V., HAL Allergy B.V., LETIPharma, AstraZeneca, Takeda Pharmaceuticals Company Ltd, Chugai Pharmaceutical Co., Ltd, Eisai Co. Ltd, Astellas Pharma Inc. and others.
Ans: The subcutaneous immunotherapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
Ans: The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?